News

BASF Adopts BrightSpec’s Broadband MRR Technology for Structural Elucidation

BrightSpec announced the start of operation of a broadband Molecular Rotational Resonance spectrometer at BASF’s research center in Ludwigshafen, Germany.

BASF will utilize MRR spectroscopy for the concise structure elucidation of organic compounds where isomerism is an underlying question. Major applications comprise stereochemical analysis, including chirality, defining the composition of mixtures without purification, and the facile structural analysis of gas-phase samples. Implementing MRR as a technology was driven by Senior Principal Scientists Wolf Stegmaier and Reinhard Doetzer of BASF’s Competence Center Analytics.

“MRR is an excellent tool for elucidating structures in combination with the classical methods FTIR, MS, and NMR since it provides critical information orthogonal to them,” stated Dr. Doetzer.  He continued: “We leverage MRR to increase the accuracy and speed of the structure elucidation process, boosting our analytical productivity.  Not a day goes by when I don’t think of a sample for which MRR would be the perfect method for solving a structure-related problem.”

Dr. Wolf Stegmaier added: “In gas analysis, MRR is providing quick answers for polar analytes without gas chromatographic separation or special detection systems. Its high selectivity is a great help in the direct analysis of complex gas samples; this is particularly so for the quantification of analytes in mixtures.”

BrightSpec’s Broadband MRR provides the unique ability to identify unknown molecules directly from a crude mixture.  In conjunction with modern quantum-mechanical calculations, MRR allows identifying the unequivocal three-dimensional structure of a molecule without reference standard or front-end separation. This combination increases sample throughput and drastically reduces the cost for many  applications across the Pharmaceutical and Chemical industries.

Director of Business Development at BrightSpec, Dr. Christopher Thompson, commented: “We are thrilled that BASF has adopted our MRR platform into their analytical workflows.  The installation is a testament to the capabilities of the entire BrightSpec team.  The close partnership between scientists at BrightSpec and BASF will ensure the success of the Broadband MRR over the coming years.”

Walter Colsman, BrightSpec’s CEO, stated, “I am extremely proud to officially announce our relationship with BASF. Both companies see the broad potential for MRR at BASF, extending beyond the lab and into operations, and we will work together to develop BASF’s MRR platform.  For example, BASF’s broadband MRR will help develop routine applications that are suitable to run on BrightSpec’s isoMRR, enabling rapid, targeted applications such as online process analytics or quality control.”

Recent News

06/29/2022

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate,

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual

06/20/2022

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by